3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Status
Recruiting
3
Withdrawn
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Prostatic Neoplasms
34
Prostate Cancer Metastatic
3
Neoplasm Metastasis
3
Prostate CA
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Triple Negative Breast Neoplasms
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Oligometastatic Prostate Cancer
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Intraprostatic Prostate Cancer
1
Genital Diseases, Male
1
Breast Neoplasms
1
Adenocarcinoma
1
Interventions
Radiosurgery
3
Androgen Antagonists
3
pembrolizumab
1
fludrocortisone acetate
1
enzalutamide
1
darolutamide
1
cabazitaxel
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Prednisone
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Hydrocortisone
1
Gonadotropin-Releasing Hormone
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Prostate Cancer Metastatic
×
Androgen Antagonists
×
Clear all
NCT04916613
2026-04-28
GETUG-AFU 40
UNICANCER
Phase 3
Recruiting
300 enrolled
NCT04983095
2026-02-17
METRO
Umeå University
Phase NA
Recruiting
118 enrolled
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled